Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7581895rdf:typepubmed:Citationlld:pubmed
pubmed-article:7581895lifeskim:mentionsumls-concept:C0042776lld:lifeskim
pubmed-article:7581895lifeskim:mentionsumls-concept:C0184511lld:lifeskim
pubmed-article:7581895lifeskim:mentionsumls-concept:C0036043lld:lifeskim
pubmed-article:7581895lifeskim:mentionsumls-concept:C1882508lld:lifeskim
pubmed-article:7581895lifeskim:mentionsumls-concept:C0072434lld:lifeskim
pubmed-article:7581895pubmed:issue2lld:pubmed
pubmed-article:7581895pubmed:dateCreated1995-12-28lld:pubmed
pubmed-article:7581895pubmed:abstractTextA virus removal system based on tangential flow filtration was introduced into a Factor IX production process. Beside the intended virus reduction potency of filter membranes, an additional purification effect could be achieved. This purification effect was evaluated in detail by means of sodium dodecyl sulphate-polyacrylamide gel electrophoresis and size-exclusion HPLC. High-molecular-mass impurities were retained by the membrane, thus increasing the specific activity of the product.lld:pubmed
pubmed-article:7581895pubmed:languageenglld:pubmed
pubmed-article:7581895pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7581895pubmed:citationSubsetIMlld:pubmed
pubmed-article:7581895pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7581895pubmed:statusMEDLINElld:pubmed
pubmed-article:7581895pubmed:monthJullld:pubmed
pubmed-article:7581895pubmed:issn1572-6495lld:pubmed
pubmed-article:7581895pubmed:authorpubmed-author:SchwinnHHlld:pubmed
pubmed-article:7581895pubmed:authorpubmed-author:BiesertLLlld:pubmed
pubmed-article:7581895pubmed:authorpubmed-author:HofferLLlld:pubmed
pubmed-article:7581895pubmed:authorpubmed-author:JosicDDlld:pubmed
pubmed-article:7581895pubmed:issnTypePrintlld:pubmed
pubmed-article:7581895pubmed:day21lld:pubmed
pubmed-article:7581895pubmed:volume669lld:pubmed
pubmed-article:7581895pubmed:ownerNLMlld:pubmed
pubmed-article:7581895pubmed:authorsCompleteYlld:pubmed
pubmed-article:7581895pubmed:pagination187-96lld:pubmed
pubmed-article:7581895pubmed:dateRevised2007-10-16lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:meshHeadingpubmed-meshheading:7581895-...lld:pubmed
pubmed-article:7581895pubmed:year1995lld:pubmed
pubmed-article:7581895pubmed:articleTitleImproved virus safety and purity of a chromatographically produced factor IX concentrate by nanofiltration.lld:pubmed
pubmed-article:7581895pubmed:affiliationOctapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria.lld:pubmed
pubmed-article:7581895pubmed:publicationTypeJournal Articlelld:pubmed